Sequential gemcitabine docetaxel is increasingly viewed as a valid option for BCG unresponsive non-muscle-invasive bladder cancer (NMIBC).

Key opinion leaders examine approaches to managing skin-related side effects, such as rash, in patients on EGFR inhibitors, ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...